Skip to main content

Table 1 Baseline characteristics of patients starting tadalafil 5 mg OaD (N = 778)

From: Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities

Variable N with data  
Age, years 778  
 Median (IQR)   57 (47–65)
 18 − 65 years, n (%)   598 (76.9)
Smoking habits, n (%) 775  
 Current smoker   148 (19.0)
 Former smoker   159 (20.4)
 Never smoker   468 (60.2)
Currently drink alcohol, n (%) 775 456 (58.8)
ED severity, n (%) 775  
 Mild   160 (20.6)
 Moderate   411 (53.0)
 Severe   204 (26.3)
Duration of ED symptoms, n (%) 776  
  < 3 months   55 (7.1)
 3 to <12 months   231 (29.7)
  ≥ 12 months   490 (63.1)
ED etiology, n (%) 776  
 Mixed   343 (44.2)
 Organic   240 (30.9)
 Psychogenic   145 (18.7)
 Unknown   48 (6.2)
With penile defects, n (%) 776 24 (3.1)
With former invasive diagnostic procedure for ED, n (%) 776 150 (19.3)
Non-coital erections, n (%) 771 422 (54.7)
Decreased libido, n (%) 775 310 (40.0)
IIEF-EF at baseline, mean (SD) 776 14.5 (7.06)
EDITS total score at baseline, mean (SD) 178a 59.6 (21.27)
Previous treatment, n (%) 777  
 PDE5 inhibitor pretreated   267 (34.3)
 PDE5 inhibitor-naïve   510 (65.6)
Relevant categories of comorbidities, n (%) 778  
 At least 1 comorbidity   454 (58.4)
  Cardiovascular disorder   268 (34.5)
  Hypertension   260 (33.4)
  Dyslipidemia   144 (18.5)
  Diabetes   124 (15.9)
  Pelvic surgery   89 (11.4)
  Benign prostatic hyperplasia   49 (6.3)
  Hypogonadism   12 (1.5)
Concomitant medication, n (%) 778  
 At least 1 concomitant medication   444 (57.1)
  Antihypertensive medication   260 (33.4)
  Lipid lowering medication   152 (19.5)
  Oral antidiabetic medication   102 (13.1)
  Cardiovascular medication   94 (12.1)
  α-blockers   58 (7.5)
  5α-reductase inhibitors   14 (1.8)
  1. ED, erectile dysfunction, EDITS Erectile Dysfunction Inventory of Treatment Satisfaction, IIEF-EF International Index of Erectile Function-Erectile Function, IQR inter quartile range, N number of patients with data, n number of patients, OaD once a day, PDE5 phosphodiesterase type 5, SD standard deviation
  2. aEDITS scores at baseline were collected only in patients pretreated with PDE5 inhibitors